Claus Roehrborn, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    nymox
    Date added:
    Date updated:
    10/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Boston Scientific
    Date added:
    Date updated:
    10/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Teleflex
    Date added:
    Date updated:
    10/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    ZenFlow
    Date added:
    Date updated:
    10/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Neotract
    Date added:
    Date updated:
    10/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Glaxo Smith Kline
    Date added:
    Date updated:
    10/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Procept Biorobotics
    Date added:
    Date updated:
    10/06/2025
Return to Update Series (2022) Lesson 12: 5-Alpha Reductase Inhibitor Therapy for Benign Prostatic Hyperplasia